Discussion of the Applications and Progress of POCT and Thioredoxin Reductase Activity Testing (TrxR) in the Field of Oncology

作者: 相宁 , 曾慧慧 :北京大学药学院,北京; 张磊 :北京大学基础医学院,北京;

关键词: 恶性肿瘤肿瘤标志物POCT硫氧还蛋白还原酶(TrxR)活性检测Malignant Tumors Tumor Marker POCT TrxR Activity Testing

摘要: 目的:通过对日立7600-110全自动生化仪和日立7170 s全自动生化分析仪测定结果比对,探讨不同仪器间天门冬氨酸氨基恶性肿瘤已成为我国最常见的导致死亡的疾病。由于病因与发病机制复杂,且缺乏早期诊断的特异性指标,导致诊断和治疗滞后,病死率极高。肿瘤标志物对于肿瘤的早期发现具有重要的提示意义,但目前肿瘤标志物检测大多依赖于专业实验室,成本高,检测周期长,且在医疗资源匮乏地区难以推广。近期新兴的POCT检验模式发展迅猛,因其设备便携,获得结果迅速且操作简单,故有利于人群中肿瘤标志物的筛查。硫氧还蛋白还原酶(TrxR)活性检测,是一种新型的肿瘤标志物检测,其在体内的表达和活性水平在一定程度上反应了体内细胞的异常增生程度。因此,POCT和TrxR活性检测的联合应用将有望成为癌症预防的新策略。

Abstract: Malignant tumors are the most common lethal diseases in China. Because of the complexity of carci-nogenesis and the lack of specific markers for early diagnosis, so delayed cancer diagnosis and treatment in clinic has a very high mortality rate. Tumor marker has important significance for early screening of carcinoma. However, the current biomarker detections for neoplasm mostly depend on the professional laboratories where it is of high-cost and difficult to extend such assay service in those medically challenged places. Recently point-of-care testing (POCT) has been rapidly developed. Due to its good portability, fast results and easy operation, it is beneficial for cancer screening in human population. Thioredoxin reductase (TrxR) is a novel tumor marker whose expression and activity reflect the extent of abnormal cellular proliferation to some degree. Overall, the combined application of POCT and TrxR activity assay may be a promising strategy for cancer prevention.

文章引用: 相宁 , 张磊 , 曾慧慧 (2016) 浅谈POCT及硫氧还蛋白还原酶活性检测在肿瘤领域的应用与进展。 医学诊断, 6, 25-34. doi: 10.12677/MD.2016.61006


[1] 李福刚, 顾敏晔, 薛汉阳, 等. 浅谈POCT技术在检验医学中的应用和发展趋势[J]. 中华检验医学杂志, 2012(35): 1212-1219.

[2] Price, C.P., John, A. and Hicks, J.M. (2004) Point-of-Care Testing. AACC Press, Washington DC.

[3] 董家书, 蒋丽君. POCT的发展及应用现状[J]. 医学研究杂志, 2011, 29(10): 38.

[4] Yildiz, F. (Ed.) (2010) Advances in Food Biochemistry. CRC Press.

[5] Warsinke, A. (2009) Point-of-Care Testing of Proteins. Analytical and Bioanalytical Chemistry, 393, 1393-1405.

[6] Chin, C.D., et al. (2011) Microfluidics-Based Diagnostics of Infectious Diseases in the Developing World. Nature Medicine, 17, 1015-1138.

[7] de la Rica, R. and Stevens, M.M. (2012) Plasmonic ELISA for the Ultra-sensitive Detection of Disease Biomarkers with the Naked Eye. Nature Nanotechnology, 7, 821-824.

[8] Gaster, R.S., et al. (2009) Matrix-Insensitive Protein Assays Push the Limits of Biosensors in Medicine. Nature Medicine, 15, 1327-1332.

[9] Fan, R., et al. (2008) Integrated Barcode Chips for Rapid, Multiplexed Analysis of Proteins in Microliter Quantities of Blood. Nature Biotechnology, 26, 1373-1378.

[10] Qin, L.D., et al. (2009) Self-Powered Microfluidic Chips for Multiplexed Protein Assays from Whole Blood. Lab Chip, 9, 2016-2020.

[11] Song, Y., et al. (2013) A Multistage Volumetric Bar Chart Chip for Visualized Quantification of DNA. Journal of the American Chemical Society, 35, 16785-16788.

[12] Rosi, N.L. and Mirkin, C.A. (2005) Nanostructures in Biodiagnostics. Chemical Reviews, 105, 1547-1562.

[13] Liu, X., et al. (2008) A One-Step Homogeneous Immunoassay for Cancerbiomarker Detection Using Gold Nanoparticle Probes Coupled with Dynamic Light Scattering. Journal of the American Chemical Society, 130, 2780-2782.

[14] Lam, B., et al. (2013) Solution-Based Circuits Enable Rapid and Mul-tiplexed Pathogen Detection. Nature Communications, 4.

[15] Liu, K.J., et al. (2010) Decoding Circulating Nucleic Acids in Human Serum Using Microfluidic Single Molecule Spectroscopy. Journal of the American Chemical Society, 132, 5793-5798.

[16] Yang, Q., et al. (2012) Detection and Differential Diagnosis of Coloncancer by a Cumulative Analysis of Promoter Methylation. Nature Communications, 3.

[17] Chen, X., et al. (2008) Characterization of microRNAs in Serum: A Novel Class of Biomarkers for Diagnosis of Cancer and Other Diseases. Cell Research, 18, 997-1006.

[18] Dong, H., et al. (2013) MicroRNA: Function, Detection, and Bioana-lysis. Chemical Reviews, 113, 6207-6233.

[19] Gubala, V., et al. (2011) Point of Care Diagnostics: Status and Future. Analytical Chemistry, 84, 487-515.

[20] Song, Y., et al. (2010) Label-Free Colorimetric Detection of Single Nucleotide Polymorphism by Using Single-Walled Carbon Nanotubeintrinsic Peroxidase-Like Activity. Chemistry—A European Journal, 16, 3617-3621.

[21] Song, Y., Xu, C., Wei, W.L., Ren, J.S. and Qu, X.G. (2011) Light Regulation of Peroxidase Activity by Spiropyran Functionalized Carbon Nanotubes Used for Label-Free Colorimetric Detection of Lysozyme. Chemical Communications, 47, 9083-9085.

[22] Mousa, N.A., Jebrail, M.J., Yang, H., Abdelgawad, M., Metalnikov, P., Chen, J., Wheeler, A.R. and Casper, R.F. (2009) Droplet-Scale Estrogen Assays in Breast Tissue, Blood, and Serum. Science Translational Medicine, 1, 1ra2.

[23] Shih, S.C., Yang, H., Jebrail, M.J., Fobel, R., McIntosh, N., Al-Dirbashi, O.Y., Chakraborty, P. and Wheeler, A.R. (2012) Dried Blood Spot Analysis by Digital Microfluidics Coupled to Nanoelectrospray Ionization Mass Spectrometry. Analytical Chemistry, 84, 3731-3738.

[24] Hunter, R.A., Privett, B.J., Henley, W.H., Breed, E.R., Liang, Z., Mittal, R., et al. (2013) Microfluidic Amperometric Sensor for Analysis of Nitric Oxide in Whole Blood. Analytical Chemistry, 85, 6066-6072.

[25] Zhang, W., Kai, K., Choi, D.S., Iwamoto, T., Nguyen, Y.H., Wong, H., et al. (2012) Microfluidics Separation Reveals the Stem-Cell-Like Deformability of Tumor-Initiating Cells. Proceedings of the National Academy of Sciences of the United States of America, 109, 18707-18712.

[26] Gascoyne, P.R., Noshari, J., Anderson, T.J. and Becker, F.F. (2009) Isolation of Rare Cells from Cell Mixtures by Dielectrophoresis. Electrophoresis, 30, 1388-1398.

[27] 阮晓东. POCT: 体外诊断新突破[J]. 新经济导刊, 2013(7): 65-68.

[28] 刘存午, 贾建勋. POCT在社区卫生机构中的应用[J]. 中国医疗器械杂志, 2015, 39(2): 149-152.

[29] 李智. POCT技术在临床应用的现状与问题[J]. 中华检验医学杂志, 2012, 35(12): 1062-1065.

[30] Passegue, E. and Wagner, E.F. (2000) JunB Suppresses Cell Proliferation by Transcriptional Activation of p16INK4a Expression. The EMBO Journal, 19, 2969-2979.

[31] Davis, R.J. (2000) Signal Transduction by the JNK Group of MAP Kinases. Cell, 103, 239-252.

[32] Smart, D.K., Ortiz, K.L., Mattson, D., Bradbury, C.M., Bisht, K.S., Sieck, L.K., et al. (2004) Thioredoxin Reductase as a Potential Molecular Target for Anticancer Agents That Induce Oxidative Stress. Cancer Research, 64, 6716-6724.

[33] Lincoln, D.T., Emadi, E.M.A., Tonissen, K.F. and Clarke, F.M. (2003) The Thioredoxin-Thioredoxin Reductase System: Over-Expression in Human Cancer. Anticancer Research, 23, 2425-2433.

[34] 李方超, 曾慧慧, 李贵新, 黄琰, 傅玲. 血浆硫氧还蛋白还原酶在肺癌中表达的初步研究[J]. 实用肿瘤杂志, 2014, 29(3): 231-233.

[35] Zhou, M. and Ma, W. The Plasma Thioredoxin Reductase (TR) Activity, a Potential Diagnostic Biomarker, Is Up- Regulate in Early-Staged Non-Small Cell Lung Cancers.

[36] Cadenas, C., Franckenstein, D., Schmidt, M., Gehrmann, M., Hermes, M., Geppert, B., et al. (2010) Role of Thioredoxin Reductase 1 and Thioredoxin Interacting Protein in Prognosis of Breast Cancer. Breast Cancer Research, 12, R44.

[37] Fu, Y.R., Yang, N., Li, Y.Q., Zhao, Y.Y., Ye, S.F., Liu, L.H. and Zeng, H.H. (2014) Evaluation of Thioredoxin Reductase as a Novel Biomarker in the Diagnosis and Treatment of Breast Cancer. Journal of Chinese Pharmaceutical Sciences, 23, 711-715.

[38] Dusse, L.M.S.A., Oliveira, N.C., Rios, D.R.A. and Marcolino, M.S. (2012) Point-of-Care Test (POCT) INR: Hope or Illusion? Revista Brasileira de Cirurgia Cardi-ovascular, 27, 296-301.

[39] 周玉宝, 刘芳, 武易, 房欢. POCT检测现状与质量管理[J]. 国际检验医院杂志, 2014, 35(21): 3003.